Drugs/Recall·openFDA/drug

PRITAM INTERNATIONAL PRIVATE LIMITED — Class II: evo, Sensitive, Anticavity Fluoride Toothpaste, (potassium nitrate 5%, sodium fluoride 0.2

MediumPublished Oct 28, 2026· AI-analyzed Nov 2, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

Pritam International Private Limited has initiated an ongoing Class II recall for 'evo Sensitive Anticavity Fluoride Toothpaste' due to CGMP deviations. The recall affects the 3.5 oz Sweet Mint variant distributed by Ashtel Studios Inc.

Who it affects

This recall affects the manufacturer (Pritam International), the distributor (Ashtel Studios Inc.), and quality assurance professionals managing OTC drug product compliance.

Why it matters

A Class II recall due to CGMP deviations suggests that the FDA has identified systemic manufacturing issues that could potentially cause temporary or medically reversible adverse health consequences. For firms utilizing international contract manufacturers for OTC monographs, this highlights the necessity of robust oversight and adherence to US manufacturing standards regardless of the production site's location.

Practical takeaway

Conduct a review of contract manufacturing partner CGMP compliance, specifically for monograph-regulated OTC products. Verify that documentation for sensitive toothpaste formulations meets current quality standards to mitigate risks of cross-contamination or potency issues.

FDA source material

Class II. Reason: CGMP Deviations.. Product: evo, Sensitive, Anticavity Fluoride Toothpaste, (potassium nitrate 5%, sodium fluoride 0.24%) Sweet Mint, Net Wt. 3.5 oz (99g), Distributed by Ashtel Studios Inc., Ontario, California 91761, NDC 84140-620-35, Item # 88620 UPC8 10147 88620 3. Firm: PRITAM INTERNATIONAL PRIVATE LIMITED (Haridwar India). Status: Ongoing.

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.